Clinical Presentation
All eight patients identified with bony changes secondary to pes anserine bursitis had a history of chronic knee pain [PMID:31093712].
Diagnosis
Eight out of 542 patients (1.47%) with pes anserine bursitis exhibited radiological features including intramedullary extension and cortical scalloping, diagnosed solely based on MRI findings [PMID:31093712].
Differential Diagnosis
The unusual presentation of pes anserine bursitis with intramedullary extension and cortical scalloping can simulate neoplastic processes, highlighting the importance of accurate imaging interpretation [PMID:31093712].
Management
PDRN, noted as a substitute for glucocorticoids, was used in a case report to treat pes anserine bursitis, demonstrating potential anti-inflammatory effects without the adverse effects associated with glucocorticoids [PMID:29069005].
The case report suggests that PDRN injections offer an anti-inflammatory benefit comparable to glucocorticoids but with a potentially safer profile, avoiding issues like glucocorticoid-induced osteoporosis and mood disorders [PMID:29069005].
Key Recommendations
Given the limitations and side effects of glucocorticoid injections, this case report recommends exploring PDRN injections as an alternative treatment for patients with persistent pes anserinus bursitis [PMID:29069005]. (Evidence: Expert opinion)
References
1 Mun JU, Cho HR, Bae SM, Park SK, Choi SL, Seo MS et al.. Effect of polydeoxyribonucleotide injection on pes anserine bursitis: A case report. Medicine 2017. link 2 Colak C, Ilaslan H, Sundaram M. Bony changes of the tibia secondary to pes anserine bursitis mimicking neoplasm. Skeletal radiology 2019. link
2 papers cited of 3 indexed.